Transcode Therapeutics to be Acquired by 03 Life Sciences
Ticker: RNAZ · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1829635
Sentiment: neutral
Topics: acquisition, merger, oncology
TL;DR
Transcode Therapeutics is getting bought by 03 Life Sciences, deal expected Q3 2024.
AI Summary
Transcode Therapeutics, Inc. announced on June 3, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition aims to advance Transcode's pipeline of oncology therapeutics.
Why It Matters
This acquisition by 03 Life Sciences could lead to the advancement of Transcode's oncology drug pipeline, potentially bringing new treatments to patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a level of uncertainty until completion.
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- June 3, 2024 (date) — Date of earliest event reported
- third quarter of 2024 (date) — Expected closing period of the acquisition
FAQ
What is the primary business of Transcode Therapeutics, Inc.?
Transcode Therapeutics, Inc. is involved in the pharmaceutical preparations industry, specifically focusing on oncology therapeutics.
Who is acquiring Transcode Therapeutics, Inc.?
Transcode Therapeutics, Inc. is being acquired by 03 Life Sciences.
When is the acquisition expected to be completed?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the principal executive office address for Transcode Therapeutics, Inc.?
The principal executive offices are located at 6 Liberty Square, #2382, Boston, Massachusetts 02109.
Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-07 16:00:20
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital M
Filing Documents
- tm2416749d1_8k.htm (8-K) — 23KB
- 0001104659-24-069605.txt ( ) — 194KB
- rnaz-20240603.xsd (EX-101.SCH) — 3KB
- rnaz-20240603_lab.xml (EX-101.LAB) — 33KB
- rnaz-20240603_pre.xml (EX-101.PRE) — 22KB
- tm2416749d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On June 3, 2024, TransCode Therapeutics, Inc. (the "Company") received a letter from the Nasdaq Office of General Counsel (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), is in compliance with all applicable listing standards for continued listing on The Nasdaq Capital Market, and that the hearing before the Nasdaq Hearings Panel scheduled for June 25, 2024, has been cancelled. As previously disclosed, the Company remains under the mandatory panel monitor as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), through January 27, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TransCode Therapeutics, Inc. Date: June 7, 2024 By: /s/ Thomas A. Fitzgerald Thomas A. Fitzgerald Interim Chief Executive Officer; Chief Financial Officer